Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.

Finkelstein, Joel S, Hang Lee, Arun Karlamangla, Robert M Neer, Patrick M Sluss, Sherri-Ann M Burnett-Bowie, Karin Darakananda, et al. 2020. “Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women’s Health Across the Nation.”. The Journal of Clinical Endocrinology and Metabolism 105 (4): e1862-71.

Abstract

BACKGROUND: A test that helps predict the time to the final menstrual period (FMP) has been sought for many years.

OBJECTIVE: To assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP.

DESIGN: Prospective longitudinal cohort study.

SETTING: The Study of Women's Health Across the Nation.

PARTICIPANTS AND MEASUREMENTS: AMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL.

MAIN OUTCOME MEASURE: Areas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed.

RESULTS: AUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h<48 years of age to 79% at ≥51 years. The probability that a woman with an AMH >100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old.

CONCLUSIONS: AMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.

Last updated on 02/06/2026
PubMed